Healthequity (NASDAQ:HQY) issued an update on its FY20 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $1.23-1.29 for the period, compared to the Thomson Reuters consensus estimate of $1.31. The company issued revenue guidance of $333-339 million, compared to the consensus revenue estimate of $336.89 million.Healthequity also updated its FY 2020 guidance to $1.23-1.29 EPS.
Shares of NASDAQ HQY traded up $0.71 during mid-day trading on Monday, hitting $82.87. The company had a trading volume of 1,083,638 shares, compared to its average volume of 871,417. Healthequity has a 12 month low of $50.29 and a 12 month high of $101.58. The stock has a market cap of $5.10 billion, a PE ratio of 153.46, a PEG ratio of 2.68 and a beta of 1.72.
Several research firms recently issued reports on HQY. BidaskClub raised shares of Healthequity from a buy rating to a strong-buy rating in a research report on Saturday. Bank of America reissued a neutral rating and issued a $82.00 price target (up previously from $67.00) on shares of Healthequity in a research report on Friday, March 1st. Zacks Investment Research lowered shares of Healthequity from a hold rating to a sell rating in a research report on Wednesday, February 27th. Cantor Fitzgerald increased their price target on shares of Healthequity from $80.00 to $83.00 and gave the stock an overweight rating in a research report on Thursday, February 7th. Finally, Chardan Capital reissued a buy rating and issued a $78.00 price target (down previously from $82.00) on shares of Healthequity in a research report on Thursday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $87.85.
In other news, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 22nd. The shares were sold at an average price of $60.81, for a total transaction of $243,240.00. Following the completion of the sale, the vice president now owns 79,200 shares of the company’s stock, valued at $4,816,152. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Delano Ladd sold 6,875 shares of the firm’s stock in a transaction that occurred on Wednesday, February 20th. The stock was sold at an average price of $78.00, for a total transaction of $536,250.00. Following the sale, the executive vice president now directly owns 14,340 shares of the company’s stock, valued at approximately $1,118,520. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,875 shares of company stock valued at $1,332,090. Company insiders own 4.00% of the company’s stock.
WARNING: This article was originally published by Zolmax and is owned by of Zolmax. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://zolmax.com/investing/healthequity-hqy-releases-fy20-earnings-guidance/2972959.html.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Article: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.